Indian FDA Approves the First Autologous Dendritic Cell-based Immuno-oncology Product, APCEDEN®

NEW YORK, April 5, 2017 /PRNewswire/ -- A first-of-its-kind Indian biotechnology company, APAC Biotech, was granted with a commercial license by Indian FDA (CDSCO - Central Drugs Standard Control Organization) to market product, APCEDEN®, a Dendritic cell-based autologous Immuno-oncology product for four cancer indication namely Prostate, Ovarian, Colo-rectal and Non Small Cell Lung carcinoma. (Logo: http://mma.prnewswire.com/media/486747/APAC_Biotech_Logo.jpg ) The Indian Food and Drug Administration authorities, after their stringent review of the application, have issued the commercial license (Form 46) to conduct a post marketing surveillance on statistically significant number of patients for each indication. Other products namely STEMPEUCEL®, an allogeneic-cultured mesenchymal cells from Stempeutics and OSSORON®, an autologous-cultured adult osteoblast and CHONDRON®, an autologous-cultured adult chondrocyte from Regenerative Medical Services, Mumbai, also received the marketing license at the same time. "The past decades have seen revolutionary progress in the development and application of cell and genetic engineering in an effort to personalize the treatment of cancer. We are now confident that it is possible to treat cancer patients using this approach as observed during clinical trials across India. The results are encouraging and mark a potential new paradigm in treating these solid tumors that do not respond to standard therapies," said a leading oncologist, Dr. Ashok Vaid.

Read more...

DENDRITIC CELL THERAPY FOR CANCER

APAC BIOTECH strives to find roots of cancer - the world's alarming disease, by transforming the promise of technology and knowledge of biology into therapies that have the power to restore health and even save lives of cancer patients.We are providing Dendritic cell therapy for cancer. We are focused primarily on the research of customised autologous cell based therapy for cancer in India.

COLORECTAL CANCER

60% of Colon Cancer Deaths could be avoided if everyone aged 50 or older were screened regularly.

LUNG CANCER

One day Lung Cancer will be a thing from the past.

OVARY CANCER

Most women with ovarian cancer develop resistance to conventional chemotherapy drugs.

PROSTATE CANCER

1 in 6 men will be diagnosed with prostate cancer during his lifetime.

About APAC Biotech

APAC Biotech Pvt.Ltd. is a leading biotechnology company which is involved in research based Dendritic cell based therapy and preparing the formulation to impede the growth of cancer cells. Our endeavour is to improve the life expectancy by providing safe and effective cell based therapy for cancer patients. Our formulation has been developed after a thorough research based on the principles of immunotherapy.

APAC BioTech

APAC BIOTECH strives to find roots of cancer - the world's alarming disease, by transforming the promise of technology and knowledge of biology into therapies that have the power to restore health and even save lives of cancer patients.

Technology

Dendritic Cells are antigen presenting cells and have high level of major histocompatibility complex, costimulatory molecules and cell adhesion molecules which are essential for antigen presentation.

R & D

APAC BIOTECH carefully designs its' research study projects that determine the effectiveness of the cancer therapy, under the supervision of highly qualified professional investigators.

Apac Biotech has a group of Qualified Researchers and doctors which help in the Research & Development activities. We have a 1000 class clean room facility, with state of art equipment. The driving force behind our research team is to constantly improve the quality sufferers.

Our Vision

To find the roots of cancer andto improve the quality of life by immunology based Dendritic cell based therapy.

Who we are?

APAC Biotech Pvt.Ltd. is a leading biotechnology company which is involved in research based Dendritic cell based therapy and preparing the formulation to impede the growth of cancer cells.

Our endeavour is to improve the life expectancy by providing safe and effective cell based therapy for cancer patients. Our formulation has been developed after a thorough research based on the principles of immunotherapy.

Our Team

ARUN MEHRA-Chief Executive Officer

ArunMehra is a visionary entrepreneur, responsible for developingdendritic cell immunotherapy at a commercial scale in India.

Have a question or need to Contact?

Apac Biotech Pvt Ltd.

69, Jacranda Marg , DLF PHASE II. GURGAON, INDIA.
Mob: +91- 9958000827 Tel: 0124-4207575
Email: info@apacbiotech.com
Website : www.apacbiotech.com